Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Longeveron ( (LGVN) ) has issued an announcement.
On August 27, 2025, Longeveron Inc. announced a leadership change with CEO Wa’el Hashad stepping down to pursue other opportunities. Than Powell, the current Chief Business Officer, was appointed as interim CEO effective September 4, 2025. Dr. Joshua Hare, the company’s founder and Chief Science Officer, was appointed as Executive Chairman of the Board. This transition occurs as Longeveron continues to advance its stem cell therapy pipeline, with pivotal Phase 2b clinical trials underway for laromestrocel, and plans for a national search to identify a permanent CEO. The company remains focused on leveraging its stem cell technology to benefit patients and shareholders.
The most recent analyst rating on (LGVN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.
Longeveron’s overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. Technical analysis further indicates bearish momentum. While the earnings call highlighted strategic progress, financial uncertainties and increased expenses weigh heavily on the score.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs. The company’s lead investigational product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy with potential applications across various disease areas, including hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron has received multiple FDA designations for its development programs, highlighting its focus on innovative stem cell therapies.
Average Trading Volume: 971,792
Technical Sentiment Signal: Sell
Current Market Cap: $17.22M
Learn more about LGVN stock on TipRanks’ Stock Analysis page.